ARTICLE | Emerging Company Profile
Attralus debuts with $25M series A to tackle systemic amyloidosis
Attralus looks to obtain clinical POC for first pan-amyloid therapy
September 15, 2020 1:31 AM UTC
Attralus debuted on Monday with a $25 million series A round from venBio Partners, a pan-amyloid imaging agent and a pair of candidates that can be developed for multiple types of systemic ...